Clinical Study
Peripheral Regulatory Cells Immunophenotyping in Kidney Transplant Recipients with Different Clinical Profiles: A Cross-Sectional Study
Table 2
Percentage of IL-10-producing B cells, IDO- and Tregs-circulating cells in KTR patients.
| | | HD
| CGD
| ELTGF
| ELTGF under treatment
| ELTGF w/o treatment
|
| | CD19-expressing B cells (%) | | | | | | | CD19+ | | | | | | | Mean ± s.e.m. | 11.8 ± 1.1 | 2.4 ± 1.4 | 3.9 ± 0.5 | | | | Median | 12.5 | 1.5 | 3.0 | | | | Range | 6.5–15.5 | 0.1–7.8 | 2.0–7.5 | | | | IL-10-producing B cells (%) | | | | | | | CD19+/CD38hi/IgA + | | | | | | | Mean ± s.e.m. | 81.9 ± 2.8 | 49.8 ± 5.9 | 80.3 ± 3.0 | 80.4 ± 2.9 | 80.0 ± 8.9 | | Median | 84.5 | 49.5 | 83.4 | 82.9 | 85.0 | | Range | 66.7–94.9 | 30.8–66.7 | 62.8–92.3 | 67.7–88.2 | 62.8–92.3 | | CD19+/CD38hi/IgD + | | | | | | | Mean ± s.e.m. | 27.7 ± 2.8 | 26.9 ± 3.6 | 36.0 ± 3.1 | 36.8 ± 3.9 | 34.0 ± 6.2 | | Median | 28.6 | 27.4 | 37.7 | 40.0 | 35.0 | | Range | 12.2–41.4 | 15.4–37.2 | 21.6–50.0 | 21.6–50.0 | 22.8–44.23 | | CD19+/CD38hi/IgG + | | | | | | | Mean ± s.e.m. | 58.4 ± 3.0 | 17.2 ± 4.1 | 31.4 ± 2.9 | 31.4 ± 3.5 | 31.2 ± 6.2 | | Median | 62.2 | 13.0 | 34.6 | 33.9 | 35.3 | | Range | 43.0–68.8 | 7.4–34.3 | 14.8–40.0 | 14.8–40.0 | 19.1–39.3 | | CD19+/CD38hi/IgM + | | | | | | | Mean ± s.e.m. | 21.2 ± 2.5 | 6.8 ± 3.4 | 22.7 ± 4.9 | 21.2 ± 5.4 | 26.1 ± 12.41 | | Median | 19.9 | 2.6 | 19.6 | 19.4 | 20.0 | | Range | 7.9–32.2 | 1.0–21.4 | 8.0–50.0 | 8.0–50.0 | 8.3–50.0 | | CD19+/CD38hi/CD24hi/CD5 + | | | | | | | Mean ± s.e.m. | 17.6 ± 1.4 | 4.3 ± 1.8 | 17.6 ± 3.5 | 17.0 ± 3.9 | 20.1 ± 9.8 | | Median | 16.7 | 1.0 | 20.6 | 18.6 | 25.8 | | Range | 11.3–25.0 | 1.0–13.6 | 1.0–37.5 | 1.0–37.5 | 1.0–33.3 | | CD19+/CD38hi/CD24hi/CD10 + | | | | | | | Mean ± s.e.m. | 25.3 ± 1.9 | 8.7 ± 3.9 | 11.3 ± 3.0 | 8.9 ± 2.6 | 20.6 ± 10.3 | | Median | 23.9 | 1.0 | 9.1 | 9.1 | 25.0 | | Range | 16.7–37.5 | 1.0–26.8 | 1.0–35.7 | 1.0–29.7 | 1.0–35.7 | | CD19+/CD38hi/CD24hi/CD20 + | | | | | | | Mean ± s.e.m. | 17.9 ± 3.0 | 3.1 ± 1.8 | 18.3 ± 4.3 | 17.8 ± 4.8 | 20.3 ± 11.3 | | Median | 16.05 | 1.0 | 17.1 | 14.2 | 20.0 | | Range | 7.1–43.0 | 1.0–17.1 | 1.0–44.0 | 1.0–44.0 | 1.0–40.0 | | CD19+/CD38hi/CD24hi/CD27 + | | | | | | | Mean ± s.e.m. | 23.6 ± 2.3 | 20.7 ± 4.1 | 10.9 ± 2.2 | 9.0 ± 2.3 | 18.1 ± 3.7 | | Median | 21.9 | 18.5 | 8.0 | 6.3 | 16.7 | | Range | 11.8–37.9 | 8.0–36.4 | 1.0–27.1 | 1.0–27.1 | 12.5–25.0 | | CD19+/CD38hi/CD24hi/CXCR4 + | | | | | | | Mean ± s.e.m. | 36.9 ± 1.9 | 25.0 ± 1.8 | 34.5 ± 3.0 | 35.9 ± 3.7 | 30.1 ± 5.1 | | Median | 35.2 | 25.0 | 33.3 | 35.4 | 33.3 | | Range | 29.5–50.0 | 17.2–33.3 | 20.0–50.0 | 20.0–50.0 | 20.0–36.8 | | CD19+/CD38hi/CD24hi/CXCR7 + | | | | | | | Mean ± s.e.m. | 33.6 ± 3.7 | 19.6 ± 3.9 | 34.0 ± 3.3 | 31.1 ± 3.0 | 41.7 ± 8.3 | | Median | 40.0 | 22.5 | 33.3 | 30.2 | 50.0 | | Range | 14.6–47.1 | 1.0–27.3 | 22.2–50.0 | 22.2–47.8 | 25.0–50.0 | | IDO-expressing cells (%) | | | | | | | CD123 hi/CCR6 +/IDO+ | | | | | | | Mean ± s.e.m. | 25.1 ± 1.6 | 14.9 ± 4.4 | 42.8 ± 1.2 | 42.3 ± 1.5 | 44.3 ± 1.2 | | Median | 26.7 | 11.3 | 42.8 | 42.1 | 44.4 | | Range | 10.2–29.3 | 3.7–29.2 | 36.0–48.7 | 36.0–48.7 | 42.2–46.2 | | Foxp3-expressing T cells (%) | | | | | | | CD4 +/CD25hi/Foxp3+ | | | | | | | Mean ± s.e.m. | 6.5 ± 0.5 | 4.5 ± 0.9 | 10.4 ± 0.7 | 10.5 ± 0.8 | 10.1 ± 1.5 | | Median | 6.4 | 4.5 | 9.9 | 9.8 | 10.1 | | Range | 3.5–9.5 | 1.9–7.0 | 6.5–14.1 | 6.5–14.1 | 7.6–12.6 | | CD8 +/CD28-/Foxp3+ | | | | | | | Mean ± s.e.m. | 5.0 ± 0.3 | 2.8 ± 0.7 | 6.0 ± 0.6 | 6.5 ± 0.6 | 4.7 ± 1.4 | | Median | 4.9 | 2.5 | 6.0 | 6.5 | 3.7 | | Range | 3.3–6.5 | 1.0–6.0 | 2.9–11.0 | 4.4–11.0 | 2.9–7.4 |
|
|
